论文部分内容阅读
目的探讨经皮冠脉介入术后,血尿酸(SUA)在对比剂肾病发生方面的预测价值。方法 310例患者按照对比剂肾病(CIN)分为2组,比较CIN组与非CIN组的基线资料;且SUA与CIN风险的相关性通过多因素Logistic回归分析评估。结果 310例患者中发生CIN 45例(14.5%),CIN组SUA较非CIN组明显升高,差异有统计学意义(P<0.05)。SUA、肾功能不全、女性、高龄(>75岁)、糖尿病、大剂量对比剂(>200 ml)、高敏C-反应蛋白及LVEF<40%均是CIN的独立危险因素。结论 SUA可成为经皮冠脉介入术(PCI)后发生CIN简捷、可靠的指标。
Objective To investigate the predictive value of serum uric acid (SUA) in the development of contrast-induced nephropathy after percutaneous coronary intervention. Methods 310 patients were divided into two groups according to contrast-induced nephropathy (CIN). The baseline data of CIN group and non-CIN group were compared. The correlation between SUA and CIN risk was evaluated by multivariate logistic regression analysis. Results Among 310 patients, CIN was found in 45 cases (14.5%). SUA in CIN group was significantly higher than that in non-CIN group (P <0.05). SUA, renal insufficiency, women, elderly (> 75 years), diabetes, high dose contrast agent (> 200 ml), high-sensitivity C-reactive protein and LVEF <40% were all independent risk factors for CIN. Conclusions SUA can be a simple and reliable index of CIN after percutaneous coronary intervention (PCI).